Overview
RYTM market data
Price History
RYTM price chart · 1M
- O
- 108.19
- H
- 112.00
- L
- 108.19
- C
- 109.94
- Vol
- 31,855.00
- Source
- US equities market feed
- Observed
- Aug 21, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $108.19
- Previous Close
- $108.82
- Day High
- $112.00
- Day Low
- $108.19
- 52 Week High
- $119.66
- 52 Week Low
- $74.50
- 7 Day Return
- -4.71%
- 30 Day Return
- +5.72%
- 90 Day Return
- +22.37%
- 1 Year Return
- +22.76%
- Daily Notional Volume
- $3.5M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.02 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.00 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -85.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $74.50 – $122.20 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $8.1B · P/B 26.45 · P/S 33.92.
Company News
Rhythm Pharmaceuticals Receives Marketing Authorization For IMCIVREE From Japan's Ministry Of Health To Treat Acquired Hypothalamic ObesityBenzinga · Aug 24, 2026, 1:28 PM
Why Is Rhythm Pharmaceuticals Stock Trading Higher On Wednesday?Benzinga · Aug 12, 2026, 5:18 PM
Rhythm Pharmaceuticals Says UK MHRA Expands IMCIVREE Marketing Authorization To Acquired Hypothalamic Obesity In Patients 4 And Older, Grants Orphan Drug DesignationBenzinga · Aug 11, 2026, 12:03 PM
JP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $146Benzinga · Aug 7, 2026, 4:44 PM
Citigroup Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $143Benzinga · Aug 5, 2026, 7:20 PM
RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $155Benzinga · Aug 5, 2026, 5:06 PM
Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Raises Price Target to $160Benzinga · Aug 5, 2026, 3:11 PM
Full Transcript: Rhythm Pharmaceuticals Q2 2026 Earnings CallBenzinga · Aug 4, 2026, 1:33 PM
8-K filing — RHYTHM PHARMACEUTICALS, INC. (RYTM)SEC EDGAR · Aug 4, 2026, 11:49 AM
Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic ObesityGlobenewswire Inc · Aug 4, 2026, 11:15 AM